Suchergebnisse - "talazoparib"

PubPharm (306)

1

First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC : Applying clinical study findings to clinical practice in the United States

enthalten in: Cancer treatment reviews | 2024

von McKay, R. | Morgans, A. | Shore, N. | +3

2

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

enthalten in: Cancer nanotechnology | 2024

von Baldwin, P. | Yang, S. | Orriols, A. | +3

3

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2024

von Teng, Q. | Lei, Z. | Wang, J. | +9

4

TALAPRO-3 clinical trial protocol : phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

enthalten in: Future oncology (London, England) | 2024

von Agarwal, N. | Saad, F. | Azad, A. | +8

5

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer : A Quantitative Synthesis and Meta-analysis

enthalten in: European urology oncology | 2024

von Messina, C. | Giunta, E. | Signori, A. | +11

6

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Mittra, A. | Coyne, G. | Zlott, J. | +15

7

Personalized treatment with PARP inhibitors in advanced urothelial carcinoma : a case report and literature review

enthalten in: Therapeutic advances in medical oncology | 2024

von Abbas, N. | Chehade, L. | Shamseddine, A.

8

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer : the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

ErratumIn: Nat Med. 2024 Jan 31;:. - PMID 38297094

9

Development of PARP inhibitors in advanced prostate cancer

enthalten in: Therapeutic advances in medical oncology | 2024

von Bourlon, M. | Valdez, P. | Castro, E.

10

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

in: Cancer Nanotechnology | 2024

von Paige Baldwin | Shicheng Yang | Adrienne Orriols | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[31]